Karyopharm reports Q1 EPS ($2.77), consensus ($3.09)

Reports Q1 revenue $30.0M, consensus $35.12M. “We are pleased that our Phase 3 SENTRY trial in patients with JAKi-naive myelofibrosis has passed its pre-specified futility analysis and continues as planned without modifications. Our conviction in this trial is further strengthened by our new data in hard-to-treat myelofibrosis patients where we observed spleen volume reduction, symptom improvement, hemoglobin stabilization and evidence of disease modification with selinexor monotherapy, addressing all four hallmarks of the disease,” said CEO Richard Paulson. “The outcomes that we have observed from our multiple pre-clinical and clinical trials continue to suggest that selinexor may be additive, if not synergistic, when combined with ruxolitinib in JAKi-naive myelofibrosis patients. This combination holds the potential to be a much needed, new standard of care for patients with myelofibrosis.”